clinical trial · NCT00648570
Fasting Study of Escitalopram Oxalate Tablets 20 mg and Lexapro® Tablets 20 mg
HealthyEscitalopram Oxalate Tablets 20 mgLexapro® Tablets (20 mg
brief summary
The objective of this study was to investigate the bioequivalence of Mylan's escitalopram oxalate 20 mg tablets to Forest's Lexapro® 20 mg tablets following a single, oral 20 mg (1 x 20 mg) dose administered under fasting conditions.
started
Aug 1, 2004
primary completion
Oct 1, 2004
completion
Oct 1, 2004
last updated
Apr 24, 2024
official title
The Objective of This Study Was to Investigate the Bioequivalence of Mylan's Escitalopram Oxalate 20 mg Tablets to Forest's Lexapro® 20 mg Tablets Following a Single, Oral 20 mg (1 x 20 mg) Dose Administered Under Fasting Conditions.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol